human
papillomaviru
hpv
vaccin
consist
major
capsid
protein
viruslik
particl
vlp
highli
efficaci
develop
cervic
cancer
precursor
attribut
oncogen
genotyp
degre
vaccineinduc
crossprotect
also
demonstr
geneticallyrel
genotyp
speci
group
coincid
detect
crossneutralis
antibodi
studi
domain
recognis
intergenotyp
crossneutralis
antibodi
delin
crystallograph
homolog
model
predict
degre
structur
divers
loop
nonvaccin
genotyp
structur
predict
inform
design
chimer
pseudovirion
intergenotyp
loop
swap
demonstr
domain
recognis
intergenotyp
crossneutralis
antibodi
compris
residu
within
de
loop
late
region
fg
loop
data
contribut
understand
domain
recognis
vaccineinduc
crossneutralis
antibodi
specif
may
play
critic
role
vaccineinduc
crossprotect
oncogen
human
papillomaviru
hpv
genotyp
caus
infecti
agent
approxim
human
cancer
worldwid
infect
oncogen
hpv
genotyp
play
fundament
role
develop
cervic
carcinoma
one
lead
caus
cancer
death
women
also
identifi
risk
factor
associ
develop
anogenit
cancer
head
neck
cancer
oncogen
genotyp
account
ca
cervic
cancer
case
worldwid
major
oncogen
hpv
genotyp
close
relat
either
within
speci
group
respect
hpv
doublestrand
dna
genom
encapsid
within
nonenvelop
icosahedr
structur
compris
major
minor
viral
structur
protein
viral
capsid
form
stepwis
manner
wherebi
five
monom
form
intermedi
pentamer
capsom
structur
capsom
associ
form
icosahedr
structur
occup
within
capsid
unclear
upper
estim
one
monom
per
capsom
propos
monom
consist
core
strand
helix
structur
support
five
surfac
expos
loop
region
design
bc
de
ef
fg
hi
protein
mediat
primari
viral
attach
via
interact
fg
hi
loop
lysin
residu
host
heparin
sulphat
moieti
intergenotyp
amino
acid
sequenc
variat
mostli
concentr
within
surfac
expos
loop
region
appear
dictat
predominantli
typespecif
natur
neutralis
antibodi
respons
hpv
natur
infect
antibodi
major
typespecif
monoclon
antibodi
mab
neutralis
hpv
infect
recognis
one
surfac
expos
loop
cryoelectron
microscop
analysi
recent
demonstr
epitop
footprint
recognis
number
mab
includ
amino
acid
residu
multipl
loop
epitop
one
mab
includ
loop
two
neighbour
monom
major
contact
residu
predict
de
fg
loop
minor
number
contact
residu
locat
ef
hi
loop
comparison
epitop
footprint
recognis
four
mab
appear
restrict
amino
acid
residu
within
fg
loop
viruslik
particl
vlp
precipit
aluminium
salt
adjuv
basi
prophylact
vaccin
cervarix
gardasil
addit
cervarix
also
contain
monophosphoryl
lipid
clinic
trial
demonstr
vaccin
highli
efficaci
develop
cervic
cancer
precursor
anogenit
diseas
attribut
vaccin
genotyp
degre
crossprotect
also
report
oncogen
genotyp
relat
within
speci
group
relat
within
speci
group
reduct
infect
due
vaccin
type
report
vaccin
popul
support
find
vaccin
efficaci
trial
third
vlpbase
prophylact
vaccin
gardasil
recent
licens
use
follow
success
clinic
trial
vaccin
type
neutralis
antibodi
detect
serum
cervicovagin
secret
vaccin
recipi
assum
mediat
vaccineinduc
typespecif
protect
base
upon
preclin
passiv
transfer
experi
antibodi
specif
appear
recognis
region
surfac
expos
loop
exampl
vaccineinduc
neutralis
antibodi
compet
block
bind
mab
loop
epitop
crossneutralis
antibodi
also
detect
serum
cervicovagin
secret
vaccin
recipi
although
role
antibodi
specif
mediat
crossprotect
unclear
pseudovirion
psv
use
surrog
authent
virion
measur
antibodymedi
neutralis
rang
viral
system
includ
hiv
influenza
viru
sar
coronaviru
hpv
hpv
psv
gener
repres
genotyp
refer
sequenc
vaccineinduc
neutralis
antibodi
recognis
bind
antigen
domain
repres
psv
crossneutralis
antibodi
detect
less
frequent
lower
titr
vaccin
type
neutralis
antibodi
addit
crossreact
antibodi
specif
demonstr
essenti
speciesgroup
specif
reactiv
breadth
crossneutralis
antibodi
respons
differ
speci
group
crossneutralis
antibodi
gener
respons
vlpbase
hpv
vaccin
indic
protein
vaccin
genotyp
harbour
immunogen
domain
share
sequenc
andor
structur
similar
protein
nonvaccin
genotyp
within
present
studi
crystallograph
homolog
model
use
predict
structur
differ
loop
nonvaccin
genotyp
data
inform
design
gener
chimer
psv
intergenotyp
loop
swap
delin
specif
domain
recognis
hpv
vaccineinduc
crossneutralis
antibodi
identif
antigen
domain
contribut
understand
virushost
interact
induc
respons
vaccin
gener
homolog
model
repres
genotyp
crystal
structur
capsom
protein
data
bank
pdb
code
use
templat
amino
acid
sequenc
repres
psv
model
three
amino
acid
residu
differ
sequenc
crystal
psv
two
positon
ef
loop
one
posit
fg
loop
sequenc
differ
appear
advers
impact
upon
qualiti
homolog
model
global
model
qualiti
estim
gmqe
score
homolog
model
repres
remain
genotyp
produc
gmqe
score
crystal
structur
capsom
pdb
code
use
control
evalu
structur
accuraci
psv
homolog
model
base
upon
crystal
structur
pairwis
comparison
homolog
model
crystal
structur
superimposit
demonstr
root
mean
squar
rm
deviat
predict
loop
structur
differ
pairwis
model
comparison
carri
psv
homolog
model
homolog
model
individu
nonvaccin
psv
loop
fig
analys
predict
chang
two
model
fig
distanc
alter
loop
structur
summaris
fig
superimposit
nonvaccin
homolog
model
onto
homolog
model
gener
follow
rm
deviat
estim
loop
distanc
homolog
model
consid
signific
distanc
measur
nonvaccin
genotyp
individu
loop
greater
rm
valu
gener
pairwis
comparison
homolog
model
structur
chang
bc
loop
predict
nonvaccin
genotyp
except
fig
shift
bc
loop
compar
rang
mean
sd
fig
predict
structur
chang
appear
attribut
insert
addit
amino
acid
residu
bc
loop
pro
ala
ser
gli
gli
asn
comparison
structur
chang
de
loop
predict
homolog
model
repres
nonvaccin
genotyp
compar
fig
de
encircl
lumen
capsom
fig
loop
contain
insert
delet
within
amino
acid
sequenc
nonvaccin
genotyp
rel
nonvaccin
homolog
model
predict
structur
chang
ef
loop
compar
model
fig
genotyp
singl
amino
acid
residu
delet
within
ef
loop
correspond
gli
within
ef
loop
may
contribut
toward
mean
ef
loop
shift
compar
fig
contrast
predict
structur
chang
ef
loop
underpin
amino
acid
residu
insert
delet
comparison
scientif
report
doi
structur
chang
fg
loop
predict
fig
mean
fg
loop
shift
compar
respect
fig
genotyp
fg
loop
amino
acid
residu
delet
correspond
ser
gli
insert
asn
ser
comparison
appear
influenc
predict
structur
chang
fg
amino
acid
sequenc
contain
residu
delet
insert
comparison
structur
chang
fg
loop
predict
nonvaccin
genotyp
compar
hi
loop
amino
acid
residu
delet
hi
f
loop
colourcod
genotyp
g
heatmap
repres
predict
distanc
mean
loop
homolog
model
repres
nonvaccin
genotyp
key
indic
distanc
indic
possibl
resolv
potenti
differ
loop
correspond
thr
within
hi
loop
three
homolog
model
repres
nonvaccin
genotyp
predict
structur
chang
compar
homolog
model
within
hi
loop
comparison
structur
chang
predict
fig
design
gener
chimer
psv
predict
structur
differ
loop
nonvaccin
psv
compar
psv
use
inform
design
chimer
psv
intergenotyp
loop
swap
reason
loop
nonvaccin
genotyp
present
similar
topographi
correspond
loop
like
recognis
vaccineinduc
crossneutralis
antibodi
base
upon
rational
de
loop
consid
candid
investig
base
upon
predict
structur
similar
de
loop
nonvaccin
genotyp
compar
fig
contrast
frequenc
predict
structur
diverg
observ
bc
ef
loop
fig
nonvaccin
genotyp
negat
investig
two
loop
fg
hi
loop
fig
f
chosen
investig
base
upon
predict
structur
similar
nonvaccin
genotyp
frequent
recognis
crossneutralis
antibodi
panel
chimer
psv
intergenotyp
de
fg
hi
loop
swap
isol
combin
design
gener
loop
swap
made
genotyp
recognis
crossneutralis
antibodi
chosen
background
control
sinc
crossneutralis
antibodi
demonstr
minim
recognit
genotyp
number
amino
acid
residu
substitut
differ
three
loop
de
longest
loop
five
posit
residu
vari
thirti
residu
long
fg
loop
eleven
variabl
posit
whilst
hi
shortest
loop
vari
nine
sixteen
amino
acid
posit
psv
either
backbon
singl
de
fg
hi
doubl
defg
dehi
fghi
tripl
defghi
loop
swap
fig
gener
similarlys
particl
particletoinfect
pi
ratio
exampl
psv
backbon
produc
median
pi
ratio
iqr
compar
pi
ratio
iqr
produc
psv
backbon
fig
crossneutralis
antibodi
recognit
specif
domain
thirtysix
hpv
vaccine
sera
cervarix
n
gardasil
n
test
chimer
psv
crossneutralis
titr
gener
chimer
psv
backbon
compar
psv
whilst
titr
gener
chimer
psv
backbon
compar
psv
fig
reason
introduct
loop
backbon
would
result
reduct
crossneutralis
antibodi
recognit
incorpor
hi
loop
alon
result
reduct
crossneutralis
antibodi
recognit
howev
incorpor
de
loop
fig
reduc
crossneutralis
antibodi
recognit
median
iqr
wilcoxon
pair
signedrank
test
p
largest
impact
singl
combin
loop
swap
observ
fg
loop
alon
result
median
decreas
crossneutralis
antibodi
recognit
iqr
p
compar
psv
transfer
crossneutralis
antibodi
recognit
support
either
introduct
de
hi
loop
backbon
signific
effect
crossneutralis
antibodi
recognit
produc
geometr
mean
titr
gmt
ci
p
ci
p
respect
compar
psv
titr
ci
fig
convers
introduct
fg
loop
backbon
significantli
finemap
crossneutralis
antibodi
epitop
footprint
order
predict
residu
within
de
fg
loop
may
involv
epitop
footprint
recognis
vaccineinduc
crossneutralis
antibodi
de
fg
loop
amino
acid
sequenc
align
fig
amino
acid
posit
vaccin
type
crossneutralis
antibodi
target
share
residu
background
control
identifi
de
ala
fg
loop
ser
gli
ser
ala
ala
ser
residu
select
undergo
sitedirect
mutagenesi
determin
contribut
epitop
footprint
recognis
crossneutralis
antibodi
alongsid
addit
site
residu
differ
de
phe
gli
pro
fg
ser
thr
fig
panel
seven
chimer
psv
backbon
de
fg
loop
swap
gener
chimer
psv
harbour
singl
doubl
amino
acid
residu
switch
incorpor
either
de
fg
loop
wherebi
amino
acid
present
swap
amino
acid
present
posit
fig
psv
particl
gener
similar
size
similar
pi
ratio
subset
twentyfour
hpv
vaccine
sera
cervarix
n
gardasil
n
origin
panel
thirtysix
test
seven
new
chimer
psv
crossneutralis
titr
gener
compar
chimer
psv
backbon
de
fg
loop
fig
within
de
loop
amino
acid
switch
result
signific
reduct
crossneutralis
antibodi
recognit
howev
dual
amino
switch
reduc
crossneutralis
antibodi
recognit
median
iqr
wilcoxon
pair
signedrank
test
p
amino
acid
switch
within
fg
separ
earli
region
number
ala
ly
late
region
gli
ser
loop
dual
amino
acid
switch
within
late
region
result
signific
reduct
crossneutralis
antibodi
recognit
howev
dramat
impact
observ
dual
amino
acid
delet
posit
produc
crossneutralis
titr
gmt
ci
p
lower
titr
observ
psv
ci
fig
contrast
dual
amino
acid
switch
posit
within
earli
region
result
reduct
crossneutralis
antibodi
recognit
map
mutagenis
residu
within
de
fg
loop
homolog
model
demonstr
posit
surfaceexpos
capsid
fig
amino
acid
posit
within
late
region
fg
biggest
impact
upon
crossneutralis
antibodi
recognit
cluster
togeth
intersect
fg
de
loop
studi
attempt
delin
domain
recognis
hpv
vaccineinduc
crossneutralis
antibodi
design
gener
chimer
psv
intergenotyp
loop
swap
test
sensit
crossneutralis
antibodi
elicit
hpv
vaccin
crossneutralis
antibodi
detect
follow
immunis
vlp
recognis
psv
repres
number
nonvaccin
genotyp
reason
assum
protein
nonvaccin
genotyp
harbour
antigen
domain
present
similar
topographi
order
identifi
domain
crystallograph
homolog
model
repres
amino
acid
sequenc
psv
gener
utilis
comparison
loop
structur
predict
structur
differ
nonvaccin
genotyp
common
bc
ef
loop
locat
outer
rim
capsom
occur
less
frequent
fg
hi
loop
structur
differ
predict
centrallyposit
de
loop
surfaceexpos
loop
region
hpv
capsid
demonstr
higher
degre
sequenc
heterogen
core
region
evid
higher
level
intraand
intergenotyp
amino
acid
variabl
locat
loop
thought
divers
driven
pressur
escap
neutralis
antibodi
target
epitop
within
surfac
expos
loop
amino
acid
residu
within
loop
also
appear
play
critic
role
maintain
capsid
stabil
initi
virushost
interact
may
account
structur
similar
predict
nonvaccin
genotyp
loop
comput
model
protein
interact
suggest
region
de
fg
loop
interact
prolinerich
region
whilst
cystein
residu
within
ef
loop
crucial
format
intercapsomer
disulphid
bond
addit
bc
fg
hi
loop
contain
lysin
residu
facilit
bind
heparin
sulfat
proteoglycan
initi
step
requir
success
hpv
infect
analysi
loop
structur
within
studi
interpret
caveat
structur
predict
deriv
homolog
model
repres
psv
amino
acid
sequenc
rather
resolv
crystal
structur
nevertheless
homolog
model
standard
approach
use
pandem
influenza
hbv
hiv
order
predict
locat
antigen
domain
site
proteinprotein
interact
pairwis
comparison
homolog
model
base
upon
capsom
crystal
structur
capsom
crystal
structur
demonstr
close
psv
prepar
backbon
de
fg
loop
amino
acid
switch
characteris
median
iqr
particl
diamet
infect
concentr
result
particletoinfect
ratio
scientif
report
doi
structur
relationship
data
impli
absenc
avail
crystal
structur
homolog
model
util
surrog
structur
predict
structur
differ
protein
loop
investig
extens
use
vlp
target
antigen
antibodi
recognit
manipul
individu
loop
insert
foreign
bcell
epitop
hiv
hbv
identifi
fg
hi
loop
immunogen
region
capsid
loop
amino
acid
point
mutat
vlp
complet
intergenotyp
loop
switch
identifi
residu
contribut
epitop
footprint
recognis
typespecif
neutralis
murin
mab
use
function
chimer
psv
measur
antibodi
specif
capabl
neutralis
psv
infect
howev
limit
singl
construct
bc
loop
swap
use
map
epitop
mab
limit
use
chimer
psv
antigen
target
may
reflect
reduc
toler
complex
particl
manipul
within
present
studi
chimer
psv
consist
intergenotyp
loop
swap
two
genotyp
within
speci
group
approach
result
success
format
function
chimer
psv
particl
chimer
psv
utilis
antigen
viru
system
includ
hiv
avian
influenza
jc
polyomaviru
map
polyclon
antibodi
recognit
specif
antigen
domain
chimer
psv
demonstr
fg
loop
necessari
suffici
epitop
footprint
signific
proport
crossneutralis
antibodi
specif
de
loop
appear
enhanc
recognit
hi
loop
appear
contribut
toward
crossneutralis
antibodi
recognit
two
loop
appear
contribut
toward
major
identifi
mab
epitop
although
instanc
singl
loop
support
epitop
footprint
exampl
bc
loop
alon
target
mab
epitop
footprint
four
neutralis
mab
recent
resolv
use
cryoelectron
microscop
analysi
demonstr
first
time
alongsid
fg
hi
loop
residu
residu
de
loop
form
core
epitop
minor
contribut
residu
bc
ef
loop
amino
acid
residu
within
de
loop
also
form
major
epitop
footprint
recognis
neutralis
human
mab
isol
hpv
vaccin
recipi
present
studi
found
de
loop
enhanc
crossneutralis
antibodi
recognit
fg
loop
within
backbon
enhanc
may
result
de
loop
residu
function
part
epitop
footprint
mayb
due
de
loop
interact
support
optimum
present
fg
loop
finemap
epitop
footprint
recognis
crossneutralis
antibodi
undertaken
wherebi
residu
de
fg
loop
amino
acid
posit
differ
subject
sitedirect
mutagenesi
alongsid
site
residu
variabl
three
genotyp
crossneutralis
antibodi
appear
primarili
target
amino
acid
residu
locat
late
region
fg
loop
particularli
amino
acid
posit
delet
result
almost
complet
loss
recognit
crossneutralis
antibodi
contrast
mutat
two
amino
acid
posit
earli
region
fg
loop
effect
upon
crossneutralis
antibodi
recognit
indic
earli
region
target
antibodi
specif
fg
loop
contain
ly
number
mediat
primari
host
attach
interact
inhibit
vivo
vaccin
induc
antibodi
provid
possibl
mechanist
reason
behind
antigen
target
fg
loop
typespecif
mab
natur
infect
antibodi
earli
region
fg
loop
known
harbour
residu
involv
epitop
footprint
typespecif
neutralis
mab
whilst
late
region
contain
major
residu
involv
epitop
footprint
typespecif
neutralis
mab
data
studi
appear
demonstr
late
region
fg
loop
harbour
amino
acid
residu
recognis
hpv
vaccineinduc
crossneutralis
antibodi
direct
overlap
exist
residu
typespecif
antibodi
footprint
observ
suggest
typespecif
antibodi
crossneutralis
antibodi
gener
recognis
differ
domain
domain
recognis
crossneutralis
antibodi
subdomin
within
epitop
footprint
typespecif
antibodi
crossneutralis
antibodi
appear
recognis
singl
nonvaccin
genotyp
multipl
nonvaccin
genotyp
addit
like
antibodi
specif
target
distinct
overlap
epitop
footprint
share
common
domain
gener
mab
crossneutralis
nonvaccin
genotyp
may
understand
domain
recognis
crossneutralis
vaccin
antibodi
relationship
typespecif
epitop
context
capsid
surfac
propos
domain
recognis
intergenotyp
crossneutralis
antibodi
elicit
hpv
vaccin
compris
residu
within
late
region
fg
loop
possibl
stabilis
one
residu
within
de
loop
crossneutralis
antibodi
target
domain
may
play
role
hpv
vaccineinduc
crossprotect
gener
homolog
model
homolog
model
creat
amino
acid
sequenc
psv
repres
sequenc
avail
http
homeccrcancergovlcopackaginghtm
use
swiss
model
http
swissmodelexpasi
org
crystal
structur
capsom
pdb
code
use
templat
target
amino
acid
sequenc
psv
model
qualiti
predict
model
measur
gmqe
score
rang
repres
expect
accuraci
result
model
score
indic
highest
level
qualiti
estim
reliabl
model
deepview
swisspdb
viewer
use
perform
pairwis
model
comparison
superimposit
predict
structur
differ
model
measur
superimposit
homolog
model
support
rm
valu
repres
averag
distanc
correspond
atom
two
model
lower
rm
valu
closer
two
model
relat
model
compar
gener
rm
valu
crystal
structur
capsom
pdb
code
use
pairwis
comparison
control
homolog
model
deepview
programm
addit
use
model
posit
amino
acid
residu
interest
homolog
model
psv
gene
backbon
reciproc
intergenotyp
loop
swap
synthesis
geneart
thermo
fisher
scientif
applic
sitedirect
mutagenesi
carri
use
quikchang
kit
stratagen
gene
subclon
plasmid
conjunct
rapid
dna
depho
ligat
kit
roch
chimer
psv
carri
luciferas
report
express
purifi
previous
describ
particl
format
size
determin
electron
microscop
analysi
neg
stain
particl
ten
psv
particl
measur
nanometr
nm
prepar
median
diamet
interquartil
rang
calcul
fig
equival
tissu
cultur
infecti
dose
tcid
estim
psv
prepar
use
spearmankarb
equat
standardis
input
tcid
use
psv
concentr
psv
stock
estim
semiquantit
western
blot
analysi
use
antibodi
abcam
unit
kingdom
particletoinfect
ratio
determin
basi
estim
particl
amount
particl
per
ng
protein
http
homeccrcancergovlcoproductionasp
ratio
normal
input
volum
tcid
gardasil
n
taken
month
receiv
final
dose
select
analysi
base
upon
crossneutralis
antibodi
titr
psv
neutralis
assay
sampl
subject
serial
dilut
antibodi
titr
result
reduct
luciferas
signal
produc
control
well
contain
psv
cell
estim
interpol
hpv
antibodi
control
reagent
includ
assay
run
alongsid
heparin
sigmaaldrich
use
posit
inhibitor
control
median
heparin
concentr
gml
psv
iqr
n
iqr
n
median
neutralis
titr
posit
antibodi
control
reagent
high
titr
psv
iqr
n
iqr
n
neg
antibodi
control
reagent
hpv
neg
titr
assay
n
statist
analysi
wilcoxon
pair
signedrank
test
use
comparison
crossneutralis
antibodi
titr
differ
psv
target
test
perform
use
statist
packag
stata
statacorp
lp
